A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
2020-07-04
عنوان الدراسة
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
داعم الدراسة
Novartis
دواء الدراسة
LEE011 (Ribociclib)
رقم بروتوكول الدراسة
CLEE011E2301
حالة الدراسة
Ongoing
موقع الدراسة
King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。